Novel actions of next-generation taxanes benefit advanced stages of prostate cancer

Clinical Cancer Research

Volumn 21, Issue 4, 2015, Pages 795-807

  De Leeuw, Renée ^a   Berman Booty, Lisa D ^a   Schiewer, Matthew J ^a   Ciment, Stephen J ^a   Den, Robert B ^a,b   Dicker, Adam P ^a,b   Kelly, William K ^a,b   Trabulsi, Edouard J ^a,b   Lallas, Costas D ^a,b   Gomella, Leonard G ^a,b   Knudsen, Karen E ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CABAZITAXEL; DOCETAXEL; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; TAXOID; TRANSCRIPTOME;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER STAGING; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CYTOLOGY; CYTOSTASIS; DRUG CYTOTOXICITY; EX VIVO STUDY; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; MITOSIS INHIBITION; MOLECULAR MECHANICS; MOUSE; MULTINUCLEAR CELL; NONHUMAN; TREATMENT RESPONSE; TUMOR XENOGRAFT; ADENOCARCINOMA; ANIMAL; CHEMICAL STRUCTURE; DNA MICROARRAY; DRUG SCREENING; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; IMMUNOBLOTTING; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; MALE; MICE; MICROSCOPY, FLUORESCENCE; MODELS, MOLECULAR; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TAXOIDS; TRANSCRIPTOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84923197175     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1358     Document Type: Article

References (42)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
3. Knudsen KE, Penning TM. Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol Metab 2010; 21:315-24.
4. Knudsen KE, Scher HI. Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res 2009;15:4792-8.
5. Berthold DR, Pond GR, Roessner M, de-Wit R, Eisenberger M, Tannock AI, et al. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res 2008;14:2763-7.
6. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: A phase 1-2 study. Lancet 2010;375:1437-46.
7. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, MillerK, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-97.
8. De-Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.
9. Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369:213-23.
10. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22.
11. De-Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castrationresistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 2010;376:1147-54.
12. Omlin A, Pezaro C, Gillessen-Sommer S. Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy. Ther Adv Urol 2014;6:3-14.
13. Abidi A. Cabazitaxel: A novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects. J Pharmacol Pharmacother 2013;4:230-7.
14. Tangen CM, Hussain MH, Higano CS, Eisenberger MA, Small EJ, Wilding G, et al. Improved overall survival trends of men with newly diagnosed M1 prostate cancer: A SWOG phase III trial experience (S8494, S8894, and S9346). J Urol 2012;188:1164-9.
15. Lorente D, de-Bono JS. Molecular alterations and emerging targets in castration resistant prostate cancer. Eur J Cancer 2014;50:753-64.
16. Stanton RA, Gernert KM, Nettles JH, Aneja R. Drugs that target dynamic microtubules: A new molecular perspective. Med Res Rev 2011;31: 443-81.
17. Mukhtar E, Adhami VM, Mukhtar H. Targeting microtubules by natural agents for cancer therapy. Mol Cancer Ther 2014;13:275-84.
18. Darshan MS, Loftus MS, Thadani-Mulero M, Levy BP, Escuin D, Zhou XK, et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res 2011;71:6019-29.
19. Van-Soest RJ, van-Royen ME, de-Morree ES, Moll JM, Teubel W, Wiemer EA, et al. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. Eur J Cancer 2013;49:3821-30.
20. Zhu ML, Horbinski CM, Garzotto M, Qian DZ, Beer TM, Kyprianou N. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res 2010;70:7992-8002.
21. Sharma A, Yeow WS, Ertel A, Coleman I, Clegg N, Thangavel C, et al. The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest 2010;120:4478-92.
22. Comstock CE, Augello MA, Goodwin JF, de-Leeuw R, Schiewer MJ, Ostrander WF Jr, et al. Targeting cell cycle and hormone receptor pathways in cancer. Oncogene 2013;32:5481-91.
23. Sharma A, Comstock CE, Knudsen ES, Cao KH, Hess-Wilson JK, Morey LM, et al. Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response inprostate cancer cells. Cancer Res 2007;67:6192-203.
24. Singh RK, Lokeshwar BL. Depletion of intrinsic expression of Interleukin-8 in prostate cancer cells causes cell cycle arrest, spontaneous apoptosis and increases the efficacy of chemotherapeutic drugs. Mol Cancer 2009;8:57.
25. Yang DR, Ding XF, Luo J, Shan YX, Wang R, Lin SJ, et al. Increased chemosensitivity via targeting testicular nuclear receptor 4 (TR4)-Oct4-interleukin 1 receptor antagonist (IL1Ra) axis in prostate cancer CD133 stem/progenitor cells to battle prostate cancer. J Biol Chem 2013;288:16476-83.
26. Centenera MM, Raj GV, Knudsen KE, Tilley WD, Butler LM. Ex vivo culture of human prostate tissue and drug development. Nat Rev Urol 2013; 10:483-7.
27. Bosco EE, Mayhew CN, Hennigan RF, Sage J, Jacks T, Knudsen ES. RB signaling prevents replication-dependent DNA double-strand breaks following genotoxic insult. Nucleic Acids Res 2004;32:25-34.
28. Burkhart DL, Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer 2008;8:671-82.
29. Chen JG, Yang CP, Cammer M, Horwitz SB.Gene expression andmitotic exit induced by microtubule-stabilizing drugs. Cancer Res 2003;63:7891-9.
30. Li Y, Li X, Hussain M, Sarkar FH. Regulation ofmicrotubule, apoptosis, and cell cycle-related genes by taxotere in prostate cancer cells analyzed by microarray. Neoplasia 2004;6:158-67.
31. Villanueva C, Bazan F, Kim S, Demarchi M, Chaigneau L, Thiery-Vuillemin A, et al. Cabazitaxel; A novel microtubule inhibitor. Drugs 2011;71: 1251-8.
32. Antonarakis ES, Armstrong AJ. Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2011;14:192-205.
33. Cisternino S, Bourasset F, Archimbaud Y, Semiond D, Sanderink G, Scherrmann JM. Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats. Br J Pharmacol 2003;138:1367-75.
34. Semiond D, Sidhu SS, Bissery MC, Vrignaud P. Can taxanes provide benefit in patients with CNS tumors and in pediatric patients with tumors? An update on the preclinical development of cabazitaxel. Cancer Chemother Pharmacol 2013;72:515-28.
35. Swanton C, Nicke B, Schuett M, Eklund AC, Ng C, LiQ, et al. Chromosomal instability determines taxane response. Proc Natl Acad Sci U S A 2009; 106:8671-6.
36. Manning AL, Dyson NJ. pRB, a tumor suppressor with a stabilizing presence. Trends Cell Biol 2011;21:433-41.
37. Manning AL, Dyson NJ. RB: mitotic implications of a tumour suppressor. Nat Rev Cancer 2012;12:220-6.
38. Manning AL, Yazinski SA, Nicolay B, Bryll A, Zou L, Dyson NJ. Suppression of genome instability in pRB-deficient cells by enhancement of chromosome cohesion. Mol Cell 2014;53:993-1004.
39. Sung M, Giannakakou P. BRCA1 regulates microtubule dynamics and taxane-induced apoptotic cell signaling. Oncogene 2014;33:1418-28.
40. Yang D, Chen MB, Wang LQ, Yang L, Liu CY, Lu PH. Bcl-2 expression predicts sensitivity to chemotherapy in breast cancer: A systematic review and meta-analysis. J Exp Clin Cancer Res 2013;32:105.
41. Inoue T, Hiratsuka M, Osaki M, Yamada H, Kishimoto I, Yamaguchi S, et al. SIRT2, a tubulin deacetylase, acts to block the entry to chromosome condensation in response to mitotic stress. Oncogene 2007;26:945-57.
42. Bonezzi K, Belotti D, North BJ, Ghilardi C, Borsotti P, Resovi A, et al. Inhibition of SIRT2 potentiates the anti-motility activity of taxanes: implications for antineoplastic combination therapies. Neoplasia 2012;14: 846-54.